Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-20
    E.g., 2018-10-20

Archive Search

5 results
12:00 AM, Oct 12, 2009  |  BC Week In Review | Clinical News  |  Clinical Results

BvdU: Phase II discontinued

and reviewed. The trial had completed enrollment of 153 patients to compare 6 cycles of RP101
plus Gemzar gemcitabine from Eli Lilly and Co. (NYSE:LLY) vs. Gemzar alone. RP101 has Orphan Drug …
adjunct to treat pancreatic cancer in the U.S. SciClone has U.S. and Canadian rights to RP101
12:00 AM, Aug 21, 2006  |  BC Week In Review | Clinical News  |  Clinical Results

RP101: Interim Phase I data

Interim data from an open-label Phase I trial in 22 patients showed that RP101 plus gemcitabine …
Bioaccelerate Holdings Inc. (BACL), New York, N.Y.   RESprotect GmbH , Dresden, Germany   Product: RP101
12:00 AM, Jun 12, 2006  |  BC Week In Review | Clinical News  |  Clinical Results

RP101: Interim Phase II data

died and 36% were followed …
Bioaccelerate Holdings Inc. (BACL), New York, N.Y.   RESprotect GmbH , Dresden, Germany   Product: RP101
12:00 AM, Sep 26, 2005  |  BC Week In Review | Clinical News  |  Clinical Results

RP101: Additional Phase I/II data

trial in 13 patients showed that 10 of the 13 patients taking 500 mg daily RP101
Bioaccelerate Holdings Inc. (BACL), New York, N.Y.   RESprotect GmbH , Dresden, Germany   Product: RP101
12:00 AM, Feb 14, 2005  |  BC Week In Review | Clinical News  |  Clinical Results

RP101: Phase I/II data

Data from an open-label, German Phase I/II trial in 13 patients showed that RP101 plus gemcitabine/cisplatin …
Bioaccelerate Holdings Inc (BACL), New York, N.Y.   RESprotect GmbH , Dresden, Germany   Product: RP101